Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2016 1
2017 1
2018 1
2021 1
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy.
Martín M, Yoder R, Salgado R, Del Monte-Millán M, Alvarez EL, Echavarría I, Staley JM, O'Dea AP, Nye LE, Stecklein SR, Bueno Muiño C, Jerez-Gilarranz Y, Cebollero M, Bueno O, Garcia-Saenz JÁ, Moreno F, Bohn U, Gomez H, Massarrah T, Khan QJ, Godwin AK, López-Tarruella S, Sharma P. Martín M, et al. Among authors: jerez gilarranz y. Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-24-0106. Online ahead of print. Clin Cancer Res. 2024. PMID: 38466643
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents.
Escudero-Vilaplana V, Collado-Borrell R, Gómez Martínez-Sagrera P, Villanueva-Bueno C, Revuelta-Herrero JL, Gonzalez-Haba E, Hoyo-Muñoz Á, Jerez Gilarranz Y, Marzal-Alfaro B, Herranz A, Martin M, Sanjurjo M. Escudero-Vilaplana V, et al. Among authors: jerez gilarranz y. J Cancer Res Clin Oncol. 2023 Jul;149(7):2855-2882. doi: 10.1007/s00432-022-04172-1. Epub 2022 Jul 6. J Cancer Res Clin Oncol. 2023. PMID: 35790560
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Escudero-Vilaplana V, Collado-Borrell R, Del Monte-Millán M, Hoyo-Muñoz A, Gómez Martínez-Sagrera P, Revuelta-Herrero JL, Marzal-Alfaro B, Gonzalez-Haba E, López-Tarruella Cobo S, Jerez Gilarranz Y, Herranz A, Sanjurjo M, Martin M. Escudero-Vilaplana V, et al. Among authors: jerez gilarranz y. Support Care Cancer. 2021 Aug;29(8):4673-4681. doi: 10.1007/s00520-021-06016-z. Epub 2021 Jan 28. Support Care Cancer. 2021. PMID: 33506273
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Sharma P, López-Tarruella S, García-Saenz JA, Khan QJ, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Monte-Millán MD, González-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortés J, Fuentes-Rivera H, Morales DB, Márquez-Rodas I, Perou CM, Lehn C, Wang YY, Klemp JR, Mammen JV, Wagner JL, Amin AL, O'Dea AP, Heldstab J, Jensen RA, Kimler BF, Godwin AK, Martín M. Sharma P, et al. Among authors: jerez gilarranz y. Clin Cancer Res. 2018 Dec 1;24(23):5820-5829. doi: 10.1158/1078-0432.CCR-18-0585. Epub 2018 Jul 30. Clin Cancer Res. 2018. PMID: 30061361 Free PMC article.
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M. Sharma P, et al. Among authors: jerez gilarranz y. Clin Cancer Res. 2017 Feb 1;23(3):649-657. doi: 10.1158/1078-0432.CCR-16-0162. Epub 2016 Jun 14. Clin Cancer Res. 2017. PMID: 27301700 Free PMC article.
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Sánchez-Bayona R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, Alva M, Echavarria I, Moreno F, Tolosa P, Herrero Lopez B, de Luna A, Lema L, Gamez Casado S, Madariaga A, López-Tarruella S, Manso L, Bueno-Muiño C, Garcia-Saenz JA, Ciruelos E, Martin M. Sánchez-Bayona R, et al. Among authors: jerez gilarranz y. Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07324-8. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38703285